<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969371</url>
  </required_header>
  <id_info>
    <org_study_id>IDE G050048</org_study_id>
    <nct_id>NCT00969371</nct_id>
  </id_info>
  <brief_title>Lenstec Tetraflex Accommodating Posterior Chamber Intraocular Lens (IOL) Clinical Investigation</brief_title>
  <official_title>Lenstec TetraFlex Accommodating Posterior Chamber Intraocular Lens (IOL)Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lenstec Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lenstec Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the following clinical protocol is to evaluate the safety and effectiveness of&#xD;
      the Lenstec Tetraflex Accommodating Posterior Chamber Intraocular Lens (IOL) for the protocol&#xD;
      inclusion/exclusion criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Lenstec TetraFlex Accommodating Posterior Chamber Intraocular Lens (IOL) is an&#xD;
      ultraviolet absorbing optical implant designed for the replacement of the human crystalline&#xD;
      lens following phacoemulsification cataract removal. The TetraFlex Accommodating Posterior&#xD;
      Chamber IOL is designed for treatment of aphakia. The lens is indicated for primary&#xD;
      implantation when a cataractous lens has been removed by phacoemulsification with circular&#xD;
      tear capsulotomy and the posterior capsule intact. The intended benefit of the TetraFlex&#xD;
      Accommodating Posterior Chamber IOL is to provide enhanced distance and near vision with an&#xD;
      increased independence from corrective lens wear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy outcome is the assessment of the % of eyes obtaining 20/40 or better distance best corrected visual acuity.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety outcome is the incidence/severity of adverse events and complications.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's functional reading ability, and other distance, near and intermediate vision testing including subjective patient survey outcomes on dependence on corrective eyewear and patient symptoms.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">470</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Lenstec Tetraflex IOL implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in Study arm received TetraFlex Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>commercially approved PCIOL implanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>posterior chamber IOL implantation</intervention_name>
    <arm_group_label>Control IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental TetraFlex Study IOL</intervention_name>
    <description>TetraFlex IOL implanted</description>
    <arm_group_label>Lenstec Tetraflex IOL implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Any race&#xD;
&#xD;
          -  Patients age at time of surgery to be 18 years or older.&#xD;
&#xD;
          -  Presence of bilateral cataract requiring cataract extraction. If only one eye is being&#xD;
             implanted with the study lens, the other eye may have had cataract extraction with IOL&#xD;
             implantation.&#xD;
&#xD;
          -  Clear intraocular media other than cataract.&#xD;
&#xD;
          -  Patients with BSCVA &lt; 20/40 or cataract with glare acuity worse than 20/30&#xD;
&#xD;
          -  Corneal Astigmatism less than 1 Diopter.&#xD;
&#xD;
          -  Good Visual Potential: Best corrected visual acuity (BCVA) projected by PAM or Pinhole&#xD;
             20/25 or better if other pathology is suspected.&#xD;
&#xD;
          -  Patient is able and willing to comply with follow-up.&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are monocular.&#xD;
&#xD;
          -  Presence of an ocular infection.&#xD;
&#xD;
          -  Greater than or equal to 1 Diopter of pre-operative corneal astigmatism.&#xD;
&#xD;
          -  Patients who are on anti-psychotic and antidepressant medication that could&#xD;
             potentially effect accommodation&#xD;
&#xD;
          -  Patients who chronically take any medication that may affect accommodation, including&#xD;
             first generation antihistamines, and anticholinergic agents.&#xD;
&#xD;
          -  Previous intraocular surgery in either eye.&#xD;
&#xD;
          -  Previous serious corneal disease.&#xD;
&#xD;
          -  Diagnosis of any of the following ocular conditions: active scleral disease, glaucoma,&#xD;
             retinal disease potentially affecting central vision, macular disease or uveitis,&#xD;
             severe dry eyes and dysthyroid eye disease&#xD;
&#xD;
          -  Subjects who may be expected to require retinal laser treatment.&#xD;
&#xD;
          -  Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or&#xD;
             other retinal disorders) that are predicted to cause future acuity losses to a level&#xD;
             of 20/30 or worse).&#xD;
&#xD;
          -  Patients requiring administration of topical ophthalmic medications other than the&#xD;
             study medications. Use of systemic corticosteroids or anti-metabolites or other&#xD;
             medications that could affect wound healing is specifically contraindicated.&#xD;
&#xD;
          -  Allergy to anesthetics or other postoperative medications.&#xD;
&#xD;
          -  Presence of any uncontrolled systemic disease (e.g. diabetes, hypertension,&#xD;
             cardiovascular disease).&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Persons who, in the determination of the investigator, are not competent to understand&#xD;
             the procedure, the actions asked of them as research subjects, or capable of&#xD;
             completing the patient satisfaction questionnaire.&#xD;
&#xD;
          -  Participation in a previous clinical trial within the 30 days prior to the start of&#xD;
             the study.&#xD;
&#xD;
          -  Persons who may not be able to complete the requirements of returning to the&#xD;
             investigator's clinic over the period of the study, or who may be difficult to locate&#xD;
             or contact on short notice. This does not preclude vacations or travel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald R Sanders, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Research</affiliation>
  </overall_official>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>posterior chamber intraocular lens</keyword>
  <keyword>PCIOL</keyword>
  <keyword>IOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

